Hormone therapy for certain early uterine lining cancers without obesity
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your biopsy or hysteroscopy confirmed either atypical endometrial hyperplasia (EAH) or low-grade stage 1 endometrial cancer (G1) with no tumor spread into the muscle layer
- Your BMI is under 30
- Imaging (MRI/CT/ultrasound) does not show spread outside the uterus
- You previously tried progestin treatment, and it either stayed stable after about 7 months or did not fully clear after about 10 months
- You need or want to keep your reproductive function or uterus
- You are able to follow the treatment and follow-up plan closely
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This trial tests a new treatment for very early endometrial cancer or a precancerous condition, aiming to help you avoid a hysterectomy and keep the chance of having children. It combines a medication (mazdutide) that helps with weight and hormone problems with a hormonal intrauterine device (LNG-IUS) to treat the lining of the womb.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
Hear when a new Endometrial Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.